Cancer News
What's Hot at 2014 San Antonio Breast Cancer Symposium?

Obesity Linked to Half a Million Cancer Cases Worldwide

JCO Withdraws Editorial on Cetuximab for Metastatic CRC

Immuno Death Ray to GI Cancers

ASH 2014: If You're Going to San Francisco…
Marker polyps do not cause colorectal cancer

High-dose interleukin-2 effective in metastatic renal cell carcinoma (mRCC) pre-treated with VEGF-targeted therapies

Possible cause discovered for failure of targeted liver cancer therapies

Possibilities for personalized cancer vaccines revealed at ESMO symposium

Limiting abnormal cell growth in tumors may be achieved by clipping proteins that package genes
New Device May Make Mammograms More Comfortable

Rx for Better Health Care: Kindness and Compassion

FDA Adds 'Boxed Warning' to Devices Used to Remove Uterine Fibroids

Get Ready for the Great American Smokeout

Blue-Eyed People May Face Higher Melanoma Risk
UCLA Researchers Identify Unique Protein Key to the Development of Blood Stem Cells

UCLA Study Finds Ancient Chinese Exercise Lessens Inflammation in Breast Cancer Survivors

New Discovery by UCLA Researchers Could Lead to More Targeted Head and Neck Cancer Therapies

Patient Profile: Liana's Looms of Love

UCLA Vice Chancellor for Research Elected to Institute of Medicine
Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: A pooled analysis of individual patient data from four randomised controlled trials

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial

First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor–positive breast cancer: A trial of the Eastern Cooperative Oncology Group

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: A randomized phase II study